Literature DB >> 34118638

Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.

Masoud Kamali1, Samantha Pegg2, Jessica A Janos3, William V Bobo4, Benjamin Brody5, Keming Gao6, Terence A Ketter7, Susan L McElroy8, Melvin G McInnis9, Dustin J Rabideau10, Noreen A Reilly-Harrington11, Richard C Shelton12, Louisa G Sylvia13, Mauricio Tohen14, Andrew Nierenberg15.   

Abstract

Bipolar disorder often follows a set progression best described in stages where advanced stages are associated with poorer outcomes. Bipolar disorder is also often characterized by a predominance of episode polarity, where some individuals experience more depressive episodes (termed predominant depressive polarity) while others experience more hypo/manic episodes (termed predominant hypo/manic polarity). We examined the associations between staging and predominant polarity with measures of illness burden and treatment outcome utilizing data from a six-month comparative effectiveness trial of lithium and quetiapine in bipolar disorder (Bipolar CHOICE). We used number of self-reported lifetime mood (depressive and hypo/manic) episodes as a proxy for staging and ratio of depressive to manic episodes to define predominant polarity. Polarity and staging were correlated with several measures of burden of illness. Childhood abuse was correlated with more lifetime mood episodes, while more depressive episodes and depressive polarity were correlated with more anxiety disorder comorbidity. Depressive polarity was also correlated with more past trials of psychotropics, particularly antidepressants. However, neither staging nor predominant polarity moderated the randomized treatment effect of lithium vs. quetiapine. Number of depressive episodes in the past year was identified as a potential predictor of overall worse treatment outcome, regardless of medication condition. In conclusion, though staging and predominant episode polarity correlated with several measures of illness burden, they were not associated with differential treatment outcomes. This could be because many of our patients presented for treatment at advanced stages of illness and further highlights the need for early intervention in bipolar disorder.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Lithium; Predominant polarity; Quetiapine; Staging

Mesh:

Year:  2021        PMID: 34118638      PMCID: PMC8319086          DOI: 10.1016/j.jpsychires.2021.05.082

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   5.250


  43 in total

1.  Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania.

Authors:  A C Swann; C L Bowden; J R Calabrese; S C Dilsaver; D D Morris
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

2.  Predominant recurrence polarity among 928 adult international bipolar I disorder patients.

Authors:  R J Baldessarini; J Undurraga; G H Vázquez; L Tondo; P Salvatore; K Ha; H-M K Khalsa; B Lepri; T H Ha; J S Chang; M Tohen; E Vieta
Journal:  Acta Psychiatr Scand       Date:  2011-12-21       Impact factor: 6.392

3.  A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool.

Authors:  A C Leon; D A Solomon; T I Mueller; J Endicott; M Posternak; L L Judd; P J Schettler; H S Akiskal; M B Keller
Journal:  J Nerv Ment Dis       Date:  2000-12       Impact factor: 2.254

4.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

5.  Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study.

Authors:  D Popovic; C Torrent; J M Goikolea; N Cruz; J Sánchez-Moreno; A González-Pinto; E Vieta
Journal:  Acta Psychiatr Scand       Date:  2013-07-19       Impact factor: 6.392

6.  Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability.

Authors:  Jodi M Gonzalez; Charles L Bowden; Martin M Katz; Peter Thompson; Vivek Singh; Thomas J Prihoda; Martha Dahl
Journal:  Int J Methods Psychiatr Res       Date:  2008       Impact factor: 4.035

7.  A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders.

Authors:  J P Feighner; R S Jacobs; R E Jackson; G Hendrickson; C H Merideth; P D O'Meara
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

8.  Staging bipolar disorder: clinical, biochemical, and functional correlates.

Authors:  I Grande; P V Magalhães; I Chendo; L Stertz; B Panizutti; G D Colpo; A R Rosa; C S Gama; F Kapczinski; E Vieta
Journal:  Acta Psychiatr Scand       Date:  2014-03-15       Impact factor: 6.392

9.  Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.

Authors:  Andrew A Nierenberg; Susan L McElroy; Edward S Friedman; Terence A Ketter; Richard C Shelton; Thilo Deckersbach; Melvin G McInnis; Charles L Bowden; Mauricio Tohen; James H Kocsis; Joseph R Calabrese; Gustavo Kinrys; William V Bobo; Vivek Singh; Masoud Kamali; David Kemp; Benjamin Brody; Noreen A Reilly-Harrington; Louisa G Sylvia; Leah W Shesler; Emily E Bernstein; David Schoenfeld; Dustin J Rabideau; Andrew C Leon; Stephen Faraone; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2016-01       Impact factor: 4.384

10.  Clinical Practice Guidelines for Management of Bipolar Disorder.

Authors:  Nilesh Shah; Sandeep Grover; G Prasad Rao
Journal:  Indian J Psychiatry       Date:  2017-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.